FromAstraZeneca ([email protected])
Subject (118)AstraZeneca demonstrates pipeline and portfolio strength across malignant and rare haematological diseases at EHA 2022
Preheader (118)AstraZeneca demonstrates pipeline and portfolio strength across malignant and rare haematological diseases at EHA 2022
Arial
Text Analysis
Body Words195
Subject Words15
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px720 px
X-Spam Score-5.2
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening
